Sarina Tanimoto

Other Executive · ARS Pharmaceuticals, Inc.

Rank #9,539 SEC EDGAR (United States) ↗ Files from United States

Details

Officer of the companyPharmaceuticals & BiotechnologySPRYSEC CIK 0001951291

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Disclosed holdings
$7.0M
1-day change
▼ 0.88%
Positions on file
1
issuers disclosed in Forms 3/4/5 and Schedules 13D/G

Disclosed holdings over time 53 weekly points

What the 1 currently disclosed position would have been worth at each week’s closing price. A rising line means the shares got more valuable, not that this person bought more.

How the line is built

Share counts are as last reported to the SEC and held constant; only prices move.

2025-09-05$6.4M – $16.3M2026-09-04

Insider activity Apr 9, 2024 – Aug 20, 2025

Sarina Tanimoto is recorded in filings to the U.S. SEC via EDGAR as officer of the company, and reported 58 transactions between Apr 9, 2024 and Aug 20, 2025. The buy and sell totals below count only codes P, S.

Why the other codes are excluded

Share awards (A), shares withheld to pay tax (F), option exercises (M) and gifts (G) also appear in the table, but they are consequences of a pay package or a private transfer, not a decision to buy or sell on the open market. Counting them would turn this into a compensation ranking.

Open-market buys (code P)
None
0 purchases on file
Open-market sales (code S)
$21.04M
51 sales on file priced rows only
All reported transactions
58
every code, including awards and exercises
Pattern
Net seller in the final 12 months of the window
last 12 months of the window

Reported transactions

Price 0.00 is a real reported figure on gifts (G) and share awards (A) — not a missing number. The 25 most recent rows are grouped into 12 lines by date, company and transaction type — open a line to see every lot with its own source link. We hold 58 on file in total. See the full history on EDGAR ↗

How to read this list

Every row is one line of one Form 4 or Form 5, with the filing it came from. Where the record carries no price at all we leave the cell empty instead of guessing one.

The shares and money on a grouped line add up only the lots listed inside that line, and only when every one of them carries the figure. Where a group mixes more than one reporting currency we leave the money blank rather than convert — no source publishes the rate that conversion would need.

  1. ARS Pharmaceuticals, Inc. SPRY S Open-market sale 37,656 shares $530.6K at $14.09 SEC filing ↗
  2. ARS Pharmaceuticals, Inc. SPRY S Open-market sale 12,344 shares $173.2K at $14.03 SEC filing ↗
  3. ARS Pharmaceuticals, Inc. SPRY S Open-market sale × 2 100,000 shares $1.17M
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    50,000 $11.67 $583.5K SEC filing ↗
    50,000 $11.67 $583.5K SEC filing ↗
  4. ARS Pharmaceuticals, Inc. SPRY S Open-market sale × 2 100,000 shares $1.32M
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    50,000 $13.16 $658.0K SEC filing ↗
    50,000 $13.17 $658.5K SEC filing ↗
  5. ARS Pharmaceuticals, Inc. SPRY M Option exercise or conversion × 3not a buy/sell decision 37,541 shares $219.8K
    The 3 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    11,876 $8.42 $100.0K SEC filing ↗
    11,876 $8.42 $100.0K SEC filing ↗
    13,789 $1.44 $19.9K SEC filing ↗
  6. ARS Pharmaceuticals, Inc. SPRY S Open-market sale × 2 100,000 shares $1.40M
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    50,000 $13.95 $697.5K SEC filing ↗
    50,000 $13.95 $697.5K SEC filing ↗
  7. ARS Pharmaceuticals, Inc. SPRY S Open-market sale × 4 100,000 shares $1.68M
    The 4 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    4,955 $17.64 $87.4K SEC filing ↗
    45,124 $16.76 $756.3K SEC filing ↗
    4,876 $17.64 $86.0K SEC filing ↗
    45,045 $16.76 $755.0K SEC filing ↗
  8. ARS Pharmaceuticals, Inc. SPRY S Open-market sale × 3 100,000 shares $1.49M
    The 3 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    1,450 $15.25 $22.1K SEC filing ↗
    48,550 $14.86 $721.5K SEC filing ↗
    50,000 $14.88 $744.0K SEC filing ↗
  9. ARS Pharmaceuticals, Inc. SPRY S Open-market sale × 2 100,000 shares $1.38M
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    50,000 $13.83 $691.5K SEC filing ↗
    50,000 $13.83 $691.5K SEC filing ↗
  10. ARS Pharmaceuticals, Inc. SPRY S Open-market sale × 2 100,000 shares $1.29M
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    50,000 $12.93 $646.5K SEC filing ↗
    50,000 $12.93 $646.5K SEC filing ↗
  11. ARS Pharmaceuticals, Inc. SPRY S Open-market sale × 2 100,000 shares $1.15M
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    50,000 $11.50 $575.0K SEC filing ↗
    50,000 $11.50 $575.0K SEC filing ↗
  12. ARS Pharmaceuticals, Inc. SPRY S Open-market sale 11,756 shares $183.5K at $15.61 SEC filing ↗

Disclosed holdings

Shares is the amount on the form; value is that amount times the closing price shown. Rows with no closing price are left blank, so they may add up to less than the headline figure.

What is not counted here

Each row is one filing you can open. Private companies, real estate, bonds and crypto are not in SEC insider filings and are therefore not counted here.

Equity positions disclosed to the SEC, with the source filing behind each row.
Issuer Ticker Security Shares Close Value Form Reported Filing
ARS Pharmaceuticals, Inc. SPRY Common Stock (indirect) 1,246,494 $5.62 $7.0M 4 EDGAR ↗

Other insiders at the same companies

People who also file with the SEC at a company where Sarina Tanimoto reports shares.

Sharing a filing does not mean they work together day to day — it means both names appear on the same issuer’s insider record.

Sources

The filings linked in the tables above are the sources for every figure on this page.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Profile record last refreshed Sep 8, 2026.